Stock of the Day

Zoetis (ZTS)

$170.43

+$1.82 (+1.1%)

Market Cap: $75.93B

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally.

The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.

Zoetis Bull Case

Here are some ways that investors could benefit from investing in Zoetis Inc.:

• The current stock price is around $170, which reflects a stable position in the market and potential for growth.
• Zoetis Inc. has received multiple upgrades from analysts, with a consensus rating of "Buy" and a target price of approximately $212.75, indicating strong future performance expectations.
• The company reported earnings per share (EPS) of $1.48, surpassing analysts' expectations, which demonstrates its ability to generate profit effectively.
• With a market capitalization of over $75 billion, Zoetis Inc. is a significant player in the animal health industry, suggesting stability and resilience.
• Recent insider trading activity shows confidence in the company's future, as executives have been actively managing their stock positions.

Zoetis Bear Case

Investors should be bearish about investing in Zoetis Inc. for these reasons:

• Insider selling has occurred, with executives reducing their holdings, which may signal concerns about the company's future performance.
• The stock has experienced fluctuations, with a 52-week high of $200.33 and a low of $139.70, indicating potential volatility.
• Some analysts have lowered their price targets, suggesting a cautious outlook on the stock's short-term performance.
• The company's debt-to-equity ratio is 1.09, which indicates a relatively high level of debt compared to equity, potentially increasing financial risk.
• Market conditions can impact the animal health sector, and any downturn could adversely affect Zoetis Inc.'s performance.

Recent News

• Zoetis Releases 2024 Sustainability Progress Update (businesswire.com)
• Zoetis Inc. (NYSE:ZTS) EVP Sells $110,840.00 in Stock (insidertrades.com)
• The "English Warren Buffett" Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks (247wallst.com)
• The “English Warren Buffett” Dumped Most of His Portfolio, But Bought Big Into These 3 Stocks (247wallst.com)
• Zoetis Inc. (ZTS) William Blair 45th Annual Growth Stock Conference (Transcript) (seekingalpha.com)
• Two biopharma stocks to consider outside of Moderna (finance.yahoo.com)
• Beat the S&P 500 With This Cash-Gushing Dividend Stock (fool.com)